FDA approves Ventana Medical's breast cancer test

06/15/2011 | Wall Street Journal, The

Ventana Medical Systems, a Roche Holding subsidiary, has received FDA approval for its Inform Dual ISH genetic test, which is designed to identify patients who are likely to benefit from Herceptin, Genentech's breast cancer drug. The test works by looking for the presence of the HER2 gene in patients' tumor samples.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC